Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P190017/S027

LIAISON MUREX HBsAg Qual, LIAISON MUREX Control HBsAg Qual and LIAISON MUREX HBsAg Confirmatory

DiaSorin, Inc. · Decision date Aug 21, 2025

FDA DECISIONP190017/S027

What did the FDA decide?

FDA records P190017/S027 as a supplement to PMA P190017, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 21, 2025.

FDA approval order statement

a manufacturing process transfer from one DiaSorin facility to another
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Microbiology
Decision date
Aug 21, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P190017/S027
Regulatory pathway
PMA supplement
Product code
LOM
Decision code
OK30
Decision date
Aug 21, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen).

Product code
LOM
FDA device class
2

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P190017/S027 received

    Application receipt date recorded by FDA.

  2. P190017/S027 · FDA decision

    30-Day Notice

  3. P190017/S028 · Related supplement

    LIAISON XL MUREX HBsAg Qual and LIAISON XL MUREX Control HBsAg Qual

  4. P190017/S026 · Related supplement

    LIAISON XL MUREX HBsAg Qual and LIAISON XL MUREX Control HBsAg Qual

Timeline entries are records held by MedtechLedger for P190017. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P190017

Product / regulatory recordCompanyPathwayDecision dateSource
DiaSorin, Inc.PMA supplementAug 28, 2025FDA
DiaSorin, Inc.PMA supplementOct 10, 2025FDA

Explore the linked device profile

Other records with product code LOM

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

DiaSorin, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1951 Northwestern Ave., Stillwater, MN, 55082

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records